Journey Medical Corporation (DERM)

Market Cap	67.77M
Revenue (ttm)	79.18M
Net Income (ttm)	-3.85M
Shares Out	19.93M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,845
Open	3.490
Previous Close	3.500
Day's Range	3.360 - 3.540
52-Week Range	1.020 - 8.110
Beta	0.81
Analysts	Strong Buy
Price Target	7.25 (+111.37%)
Earnings Date	May 9, 2024

About DERM

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 12, 2021
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: DERM

Financial Performance

In 2023, DERM's revenue was $79.18 million, an increase of 7.48% compared to the previous year's $73.67 million. Losses were -$3.85 million, -87.00% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price forecast is $7.25, which is an increase of 111.37% from the latest price.

Price Target

$7.25

(111.37% upside)

Analyst Consensus: Strong Buy